*November 2024* In this video, Jessica Donington, MD, MSCR, Melina Elpi Marmarelis, MD, and Ibiayi Dagogo-Jack, MD, discuss the next steps for biomarker testing in NSCLC. Watch here.  

*November 2024* Nicolas Girard, MD, professor, respiratory medicine, Versailles Saint Quentin University; head, Curie-Montsouris Thorax Institute, chair, Medical Oncology Department, Institut Curie, discusses de novo vs acquired resistance alterations in HER2-positive non–small cell lung cancer (NSCLC). In HER2-positive NSCLC, alterations can be broadly categorized as either de novo mutations or acquired resistance mutations, Girard begins. De novo mutations…

*November 2024* Key Takeaways Datopotamab deruxtecan targets EGFR-mutated advanced NSCLC, showing promising response and disease control rates in the TROPION-Lung05 trial. The TROPION-Lung01 trial showed non-significant overall survival improvement, leading to the withdrawal of the BLA for nonsquamous NSCLC. Safety data indicated that all patients experienced treatment-emergent adverse effects, with…

*October 2024* Abstract Purpose This multicenter, randomized, phase III clinical trial (Northern Radiation Oncology Group of China-002) focused on patients with oligo-organ metastatic non–small cell lung cancer (NSCLC) who have epidermal growth factor receptor (EGFR) mutations. We aimed to investigate whether first-line concurrent thoracic radiotherapy (TRT) and EGFR-tyrosine kinase inhibitors…

*November 2024* LCRF’s 2024 Scientific Symposium was held November 4 as part of their Lung Cancer Awareness Month activities. Joining the record-breaking group online were event lead and moderator, Kathryn O’Donnell, PhD; chat moderator, Isabel Preeshagul, DO, MBS; and speakers Brendon M. Stiles, MD; Colleen Conner Ziegler; Mark Awad, MD,…

*October 2024* Abstract Purpose This multicenter, randomized, phase III clinical trial (Northern Radiation Oncology Group of China-002) focused on patients with oligo-organ metastatic non–small cell lung cancer (NSCLC) who have epidermal growth factor receptor (EGFR) mutations. We aimed to investigate whether first-line concurrent thoracic radiotherapy (TRT) and EGFR-tyrosine kinase inhibitors…

*October 2024* In a new study published in Nature Medicine UHN researchers have identified specific DNA changes that can predict a patient’s risk of cancer spreading to the brain, offering new approaches to managing patients and improving health outcomes. The spread of cancer to the brain, known as brain metastasis, significantly reduces…

*November 2024* Highlights •EGFR-TKIs have improved outcomes for patients with EGFR-mutant NSCLC. •Acquired resistance occurs through complex and multifaceted mechanisms. •C797S mutation emerges in 6–12 % of patients treated with first-line osimertinib. •Fourth-generation EGFR-TKIs are active against common and resistance EGFR mutations. •Phase 1/2 clinical trials are ongoing, with promising activity…